Journal of Radioanalytical and Nuclear Chemistry

, Volume 304, Issue 3, pp 1285–1291 | Cite as

Preparation and biological evaluation of 166Ho-BPAMD as a potential therapeutic bone-seeking agent

  • Hassan Yousefnia
  • Naeimeh Amraei
  • Mohammad Hosntalab
  • Samaneh Zolghadri
  • Ali Bahrami-Samani


In this work 166Ho-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (166Ho-BPAMD) complex was prepared successfully with sufficient radiochemical purity of >94 % and specific activity of 244 GBq/mmol at the optimized conditions. The complex demonstrated significant stability at room temperature and in human serum at least for 24 h. Hydroxyapatite (HA) binding assay demonstrated that even at the small amount of HA, >10 mg, above 98 % of the complex is bound to HA. At the pH 7.4, LogP0/w was −1.73 ± 0.02. Both planar imaging and biodistribution studies showed major accumulation of the labelled compound in the bone tissue.


166Ho BPAMD Bone marrow ablation Scintigraphy Biodistribution 


  1. 1.
    Child AH (2003) High dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875CrossRefGoogle Scholar
  2. 2.
    Alexanian R, Barlogie B (1990) New treatment strategies for multiple myeloma. Am J Hematol 35:194–198CrossRefGoogle Scholar
  3. 3.
    Rostom AY, O’Cathail SM, Folkes A (1984) Systemic irradiation in multiple myeloma: a report on nineteen cases. Br J Haematol 58:423–431CrossRefGoogle Scholar
  4. 4.
    Cavo M, Gobbi M, Tura S (1981) Peptichemio in multiple myeloma, (preliminary results). Haematologica 66:208–215Google Scholar
  5. 5.
    Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L et al (2003) 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase I/II trials. Blood 102:2684–2691CrossRefGoogle Scholar
  6. 6.
    Palma E, Correia JDG, Campello MPC, Santos I (2011) Bisphosphonates as radionuclide carriers for imaging or systemic therapy. Mol BioSyst 7:2950–2966CrossRefGoogle Scholar
  7. 7.
    Fellnera M, Biesalski B, Bausbacher N, Kubícek V, Hermann P, Rösch F, Thews O (2012) 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 39:993–999CrossRefGoogle Scholar
  8. 8.
    Fellner M, Baum RP, Kubícek V, Hermann P, Lukeš I, Prasad V et al (2010) PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 37:834CrossRefGoogle Scholar
  9. 9.
    Calhoun JM, Cessna JT, Coursey BM, Hoppes DD, Schima FJ, Unterweger MP (1992) Standardization of holmium-166 by the CIEMAT/NIST liquid scintillation efficiency-tracing method. Radioact Radiochem. 2:38–45Google Scholar
  10. 10.
    Breitz HB, Wendt RE III, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W et al (2006) 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med 47:534–542Google Scholar
  11. 11.
    Yousefnia H, Zolghadri S, Jalilian AR, Tajik M, Ghannadi-Maragheh M (2014) Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot 94:260–265CrossRefGoogle Scholar
  12. 12.
    Pedraza-López M, Ferro-Flores G, de Murphy CA, Tendilla JI, Villanueva-Sánchez O (2004) Preparation of 166Dy/166Ho-EDTMP: a potential in vivo generator system for bone marrow ablation. Nucl Med Commun 25:615–621CrossRefGoogle Scholar
  13. 13.
    Zeevaart JR, Jarvis NV, Louw WK, Jackson GE (2001) Metal-ion speciation in blood plasma incorporating the tetraphosphonate, N, N-dimethylenephosphonate-1-hydroxy-4-aminopropilydenediphosphonate (APDDMP), in therapeutic radiopharmaceuticals. J Inorg Biochem 83:57–65CrossRefGoogle Scholar
  14. 14.
    Marques F, Gano L, Campello MP, Lacerda S, Santos I (2007) Biological evaluation of 153Sm and 166Ho complexes with tetraazamacrocycles containing methylcarboxylate and/or methylphosphonate pendant arms. Radiochim Acta 95:335–341CrossRefGoogle Scholar
  15. 15.
    IAEA-TECDOC-1340 (2003) Manual for reactor produced radioisotopes. ISBN 92-0-101103-2, ISSN 1011-4289, IAEA, AustriaGoogle Scholar
  16. 16.
    Neves M, Gano L, Pereira N, Costa MC, Costa MR, Chandia M et al (2002) Synthesis, characterization and bio-distribution of bisphosphonates 153Sm complexes: correlation with molecular modeling interaction studies. Nucl Med Biol 29:329–338CrossRefGoogle Scholar
  17. 17.
    Du XL, Zhang TL, Yuan L, Zhao YY, Li RC, Wang K, Yan SC, Zhang L, Sun H, Qian ZM (2002) Complexation of ytterbium to human transferrin and its uptake by K562 cells. Eur J Biochem 269:6082–6090CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2015

Authors and Affiliations

  • Hassan Yousefnia
    • 1
  • Naeimeh Amraei
    • 2
  • Mohammad Hosntalab
    • 2
  • Samaneh Zolghadri
    • 1
  • Ali Bahrami-Samani
    • 1
  1. 1.Nuclear Science and Technology Research Institute (NSTRI)TehranIran
  2. 2.Faculty of Engineering, Science and Research BranchIslamic Azad University (IAU)TehranIran

Personalised recommendations